Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Immunoglobulin kappa variable 6D-21 (IGKV6D-21) encodes the variable (V) region segment of the immunoglobulin kappa light chain, which participates in the formation of the antigen binding site of immunoglobulins (antibodies)[1][5]. This variable region is critical for the diversity and specificity of antibody-mediated antigen recognition; it is generated through V(D)J recombination as part of B cell development, enabling the immune system to recognize a wide array of pathogens[1]. IGKV6D-21 is a protein-coding gene, but it is catalogued as "non-functional" and participates as part of the immunoglobulin complex present in the plasma membrane and extracellular region[1][5]. It does not act as a therapeutic target (e.g., receptor/enzyme), nor is it directly targeted by drugs; its primary biological role is in antibody variability and immune defense rather than as an isolated actionable target[1][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Immunoglobulin kappa variable 6D-21 (IGKV6D-21).